Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. USO
4. VRTX
5. SPY
6. NVDA
7. LMT
8. WMT
9. CMPS
10. RIVN

Go back to Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

Dermira (DERM) Climbs 48% After Reporting Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

March 18, 2019 7:06 AM EDT

Dermira (NASDAQ: DERM) Climbs 48% After Reporting Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

... More